TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6123363
Drug: Beta-blockers (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (early intervention)
Study: 27444046
Drug: Intact oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact oxycodone 40 mg, intact OxyContin® 40 and 80 mg, crushed OxyContin® 40 mg, and placebo (Cohort 1)
Study: 27444046
Drug: Intact oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact oxycodone 20, 40, and 80 mg and placebo (Cohort 2)
Study: 26916685
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 1-3 times daily
Study: 26916685
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart 3 times daily + insulin detemir once daily
Study: 26916685
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir alone once daily
Study: 25066329
Drug: Optimised standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised standard treatment (control group)
Study: 22314121
Drug: nano-formulated diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano-formulated diclofenac 35 mg
Study: 22314121
Drug: nano-formulated diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano-formulated diclofenac 18 mg
Study: 23043637
Drug: celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 400 mg
Study: 15133754
Drug: Glipizide GITS
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide GITS AM (5-20 mg)
Study: 15133754
Drug: Glipizide GITS
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide GITS PM (5-20 mg)
Study: 15133754
Drug: Glibenclamide (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5-20 mg)
Study: 12866726
Drug: Preemptive analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive analgesia (100 mg iv tramadol before induction of anesthesia)
Study: 12866726
Drug: Preventive analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive analgesia (100 mg iv tramadol immediately after peritoneal closure)
Study: 12866726
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 mg iv tramadol immediately after operation)
Study: 7732668
Drug: Cotton-boll pectin
Normalized name: Cotton
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton-boll pectin (1 g per 100 ml of infant milk or food, 3 times a day for 45-60 days)
Study: 28711582
Drug: SM04690 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM04690 0.03 mg
Study: 28711582
Drug: SM04690 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM04690 0.07 mg
Study: 28711582
Drug: SM04690 0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM04690 0.23 mg
Study: 23357844
Drug: Clodronate 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 200 mg/lidocaine 1% (i.m.) given twice monthly
Study: 23357844
Drug: Clodronate 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 100 mg/lidocaine 1% (i.m.) given weekly
Study: 21036635
Drug: Dolasetron 12.5mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 12.5mg/d via intravenous route
Study: 19779464
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (various classes)
Study: 3347325
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide (HCT)
Study: 16450155
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hydrochlorothiazide (HCT)
Study: 10368203
Drug: MUSE (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MUSE (1 mg)
Study: 1503326
Drug: Low-molecular-weight heparinoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparinoid (ORG 10172), 750 anti-factor Xa units twice daily
Study: 1503326
Drug: Unfractionated heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin, 5000 units subcutaneously twice daily
Study: 30424980
Drug: mHELP protocols
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mHELP protocols (early mobilization, oral and nutritional assistance, and orienting communication) administered daily with usual care by a trained nurse until hospital discharge
Study: 30658375
Drug: 3% oxalic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% oxalic acid/potassium salt solution (Super Seal Desensitizer)
Study: 18196225
Drug: Fingolimod (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (5 mg single dose) + Atenolol (50 mg once daily for 5 days)
Study: 18196225
Drug: Fingolimod (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (5 mg single dose) + Diltiazem (240 mg once daily for 5 days)
Study: 10962136
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 200 mg/day for 10 days/month
Study: 8664131
Drug: 3 weekly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 weekly regimen of cisplatin 60 mg m‐2 i.v. on day 1 and etoposide 120 mg m‐2 i.v. on day 1 and 100 mg b.d. orally on days 2 and 3 alternating with cyclophosphamide 600 mg m‐2 i.v., doxorubicin 50 mg m‐2 i.v. and vincristine 2 mg i.v. all on day 1 for a maximum of six courses (3 weekly)
Study: 8664131
Drug: 10/11 day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/11 day regimen with the same drugs but with each course consisting of half the 3 weekly dose given every 10 or 11 days for a maximum of 12 courses
Study: 8664131
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life measured using a daily diary card (DDC)
Study: 1839902
Drug: Chlorthalidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (mean dose 25 mg/day)
Study: 1839902
Drug: Metoprolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (mean dose 200 mg/day)
Study: 1839902
Drug: Chlorthalidone/Metoprolol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone/Metoprolol combination (logroton)
Study: 27623757
Drug: L-arginine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (6 g)
Study: 24418244
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g cornstarch)
Study: 16000612
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with two cycles of carboplatin and paclitaxel
Study: 12800728
Drug: Lactose-containing milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-containing milk (240 mL daily for 14 days)
Study: 12800728
Drug: Lactose-hydrolyzed milk
Normalized name: MILK PROTEIN,HYDROLYZED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-hydrolyzed milk (240 mL daily for 14 days)
Study: 10483329
Drug: Naftidrofuryl (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (200 mg three times daily)
Study: 8354803
Drug: Intravenous thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolytic therapy with either streptokinase or recombinant tissue-type plasminogen activator within 7 hours of symptom onset (mean 4.8 hours)
Study: 1899433
Drug: Intravenous thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolytic therapy
Study: 26122891
Drug: Twice-weekly sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly sessions at the start of CBT
Study: 26122891
Drug: Twice-weekly sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly sessions at the start of IPT
Study: 26122891
Drug: Once-weekly sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly sessions at the start of CBT
Study: 26122891
Drug: Once-weekly sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly sessions at the start of IPT
Study: 22088518
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 - 120 mg
Study: 15259448
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibition (abciximab) in addition to dalteparin (subcutaneous)
Study: 15259448
Drug: Dalteparin (subcutaneous)
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (subcutaneous)
Study: 12847065
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NT-proBNP and creatinine clearance
Study: 15259448
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and heparin (or dalteparin)
Study: 31909725
Drug: iCBT‐I (internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT‐I (internet-delivered cognitive behavioral therapy for insomnia)
Study: 30975977
Drug: Citalopram (SSRI)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (SSRI) preceded by pindolol (5-HT1AR antagonist)
Study: 28540436
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (0.5 mg/kg, max 20 mg)
Study: 28540436
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg, max 20 mg)
Study: 26529076
Drug: 23vPPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23vPPV vaccine administered during pregnancy (at 30-36 weeks gestation)
Study: 26529076
Drug: 23vPPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23vPPV vaccine administered at birth
Study: 26529076
Drug: 23vPPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23vPPV vaccine during pregnancy (post-hoc analysis)
Study: 21540874
Drug: Supplement group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement group (28,000 IU vitamin D2 via supplement)
Study: 10735923
Drug: LAO (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAO (lansoprazole 30 mg o.d., amoxycillin 1 g b.d., ornidazole 500 mg b.d.)
Study: 10735923
Drug: LAC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (lansoprazole 30 mg o.d., amoxycillin 1 g b.d., clarithromycin 500 mg b.d.)
Study: 2869849
Drug: Nifedipine (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20, 40, and 60 mg b.i.d.)
Study: 2869849
Drug: Hydralazine (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (25, 50, and 100 mg b.i.d.)
Study: 31981364
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MTX treatment)
Study: 31981364
Drug: Dose-response association
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response association
Study: 30315150
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) add-on therapy (2700 mg/day) for 6 months
Study: 26921057
Drug: Aripiprazole adjunctive
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole adjunctive treatment (5 mg/day for 8 weeks)
Study: 26921057
Drug: Non-adjunctive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjunctive treatment (control group)
Study: 18627322
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/day for 12 weeks)
Study: 18627322
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus atorvastatin
Study: 11832257
Drug: Idoxifene 5
Normalized name: Idoxene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxifene 5 mg per day
Study: 11832257
Drug: Idoxifene 10
Normalized name: Idoxene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxifene 10 mg per day
Study: 7862181
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment with rifampin plus isoniazid for 12 months
Study: 7862181
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after 6 months for HIV-seronegative patients
Study: 1789059
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg bromocriptine po
Study: 7193614
Drug: Clomipramine (Anafranil)
Normalized name: clomipramine Oral Capsule [Anafranil]
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine (Anafranil) 10 mg daily, with an option to increase to 40 mg
Study: 30268865
Drug: Transdermal androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal androgen (AndroGel; Besins Healthcare, Brussels, Belgium)
Study: 28198147
Drug: WC, alanine-aminotransferase,
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC, alanine-aminotransferase, triglycerides/high-density lipoprotein cholesterol, and homeostasis model assessment of insulin resistance
Study: 21266301
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus voucher incentives (FV)
Study: 21266301
Drug: Fluoxetine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine without vouchers (F)
Study: 16952487
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose (10 mg) of diazepam
Study: 16952487
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose (7.5 mg) of midazolam
Study: 16952487
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose (50 mg) of ZK253
Study: 16952487
Drug: Microdose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose (100 microg) of warfarin
Study: 16952487
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose (5 mg) of warfarin
Study: 15307692
Drug: Insulin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (Group B)
Study: 15307692
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of insulin and Chinese medicine (Group C)
Study: 11398518
Drug: Prednisone therapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone therapy (duration not exceeding 3 months)
Study: 11398518
Drug: Prednisone therapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone therapy (duration 5 years on average)
Study: 3706623
Drug: 10.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg/kg metrifonate (2 doses)
Study: 3706623
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg metrifonate (2 doses)
Study: 3706623
Drug: 10.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg/kg metrifonate (1 dose)
Study: 29528180
Drug: Caregiver-only adaptation
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver-only adaptation of family-focused treatment (FFT) for 12-15 weeks
Study: 29528180
Drug: Caregiver-only adaptation
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver-only adaptation of family-focused treatment (FFT)
Study: 24588066
Drug: Treatment-as-usual only
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual only waitlist condition
Study: 18936595
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint (OS) therapy used at nighttime and for 3 hours during daytime for 7 weeks
Study: 16087791
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg twice daily for 1 week
Study: 12585182
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) plus human chorionic gonadotropin and progesterone
Study: 10352202
Drug: Intradialytic parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic parenteral nutrition (IDPN) with amino acids (AAs)
Study: 10352202
Drug: Intradialytic parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic parenteral nutrition (IDPN) without amino acids (AAs)
Study: 10352202
Drug: Intradialytic parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic parenteral nutrition (IDPN) with all three components (AAs, dextrose, lipids)
Study: 1779314
Drug: Improved ORS
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved ORS (20 g maltodextrin, 4 g glycine, 4 g glycyl‐glycine)
Study: 1811441
Drug: Standard ORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ORS (WHO formulation containing citrate)
Study: 6755855
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy
Study: 6755855
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy
Study: 28122783
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid treatment (0.8 mg daily)
Study: 28122783
Drug: Enalapril alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril alone (10 mg daily)
Study: 24299323
Drug: Pantoprazole-Mg 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole-Mg 40 mg once daily
Study: 12421192
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 10 mg/kg given at conclusion of surgery and again 3 hours later
Study: 17418554
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg twice daily
Study: 10510140
Drug: Budesonide 1600
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 1600 microg twice daily
Study: 11190754
Drug: Budesonide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (all doses)
Study: 9674293
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg/day
Study: 18672986
Drug: 0.6% eucalyptus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% eucalyptus extract chewing gum for 12 weeks (90 mg/day)
Study: 18672986
Drug: 0.4% eucalyptus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% eucalyptus extract chewing gum for 12 weeks (60 mg/day)
Study: 16551899
Drug: Milrinone initial
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone initial dose of 100 or 250 microg/kg
Study: 16551899
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV infusion of milrinone at 0.5 microg x kg(‐1) x min(‐1)
Study: 16551899
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of milrinone at 0.2 microg x kg(‐1) x min(‐1)
Study: 14666758
Drug: Shenmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai Injection (SI)
Study: 14666758
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment + SI
Study: 10700663
Drug: buspirone 0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone 0.14 mg/kg
Study: 10700663
Drug: buspirone 0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone 0.28 mg/kg
Study: 1988669
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg 3 times daily)
Study: 31494096
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg AMG 714
Study: 31494096
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg AMG 714
Study: 28735698
Drug: Timely treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely treatments for ADHD symptoms and additional support for children with lower IQ and from low-income households
Study: 23770889
Drug: Trampoline exercise
Normalized name: tramazoline
DrugBank: Tramazoline (DB13064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trampoline exercise intervention (daily individualized 20-min sessions for 12 weeks)
Study: 21794162
Drug: Post-test counseling
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-test counseling by trained counselors and monthly home visits by community support agents
Study: 15215792
Drug: Telmisartan and
Normalized name: telmisartan and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan and Ramipril combination
Study: 11239640
Drug: Extra-amniotic infusion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic infusion of PGE2 (0.5 microg/mL)
Study: 11239640
Drug: Extra-amniotic infusion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic infusion of saline
Study: 8072387
Drug: Graded doses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded doses of licorice (814 mg glycyrrhizin)
Study: 8072387
Drug: Graded doses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded doses of licorice (380 mg glycyrrhizin)
Study: 8072387
Drug: Graded doses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded doses of licorice (217 mg glycyrrhizin)
Study: 8072387
Drug: Graded doses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded doses of licorice (108 mg glycyrrhizin)
Study: 2468871
Drug: Nitrendipine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (5-20 mg b.i.d.)
Study: 2468871
Drug: Propranolol (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40-120 mg b.i.d.)